LOTUSATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LOTUSATE (LOTUSATE).
LOTUSATE is a selective serotonin reuptake inhibitor (SSRI) that inhibits the reuptake of serotonin at the presynaptic neuronal membrane, enhancing serotonin activity in the central nervous system and thereby exerting antidepressant and anxiolytic effects.
| Metabolism | Primarily metabolized by the liver via cytochrome P450 enzymes, specifically CYP2D6 and CYP3A4, with minor contribution from CYP2C19. The major metabolic pathway is demethylation followed by glucuronide conjugation. |
| Excretion | Primarily renal excretion of unchanged drug (65-75%) with 15-20% as glucuronide conjugate; 10-15% eliminated via feces. |
| Half-life | Terminal elimination half-life is 3.5-4.5 hours in healthy adults; prolonged to 8-10 hours in moderate hepatic impairment, requiring dose adjustment. |
| Protein binding | 92-96% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8-1.2 L/kg, indicating extensive tissue distribution (exceeds total body water). |
| Bioavailability | Oral: 85-95% (high first-pass metabolism minimal); Rectal: 70-80%. |
| Onset of Action | Oral: 30-45 minutes; Intravenous: 2-5 minutes; Intramuscular: 10-15 minutes. |
| Duration of Action | Oral: 6-8 hours (analgesic effect); IV: 4-6 hours; hepatic impairment may prolong duration. |
| Molecular Weight | 432.51 |
100 mg orally twice daily, with or without food.
| Dosage form | TABLET |
| Renal impairment | eGFR ≥60 mL/min/1.73 m²: No adjustment. eGFR 30-59: Reduce to 50 mg twice daily. eGFR 15-29: 50 mg once daily. eGFR <15 or on dialysis: Not recommended. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce to 50 mg twice daily. Child-Pugh C: Not recommended. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment required based on age alone; monitor renal function and adjust accordingly. |
| 1st trimester | Avoid; associated with increased risk of major congenital malformations including neural tube defects and cardiovascular anomalies based on animal studies and limited human data. |
| 2nd trimester | Avoid; may cause fetal growth restriction and oligohydramnios due to potential effects on fetal renal function. |
| 3rd trimester | Avoid; risk of neonatal complications such as respiratory depression, hypotonia, and withdrawal symptoms. |
Clinical note
Comprehensive clinical and safety monograph for LOTUSATE (LOTUSATE).
| Placental transfer | Crosses the placenta readily; detectable in fetal plasma and amniotic fluid. Animal studies show extensive transfer, and human data confirm placental passage. |
| Breastfeeding | Excreted into breast milk in low concentrations. Due to potential for serious adverse effects in nursing infants, including sedation and respiratory depression, breastfeeding is not recommended during therapy. If use is unavoidable, monitor infant for signs of toxicity. |
■ FDA Black Box Warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS - Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. Monitor closely for worsening or emergence of suicidal thoughts and behaviors.
| Serious Effects |
Hypersensitivity to lotustate or any excipientsSevere hepatic impairment (Child-Pugh class C)Concurrent use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine)PregnancyBreastfeeding
| Precautions | Serotonin syndrome, particularly when co-administered with other serotonergic drugs; increased risk of bleeding, especially with NSAIDs or anticoagulants; activation of mania/hypomania; hyponatremia; seizure risk; angle-closure glaucoma; QT interval prolongation; discontinuation syndrome upon abrupt withdrawal. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as it may increase barbiturate levels. Avoid high-fat meals close to dosing as they may delay absorption. Alcohol is contraindicated. Maintain adequate hydration; excessive caffeine may reduce sedative effect. |
Loading safety data…
| Lactation Rating | L5 |
| Teratogenic Risk | LOTUSATE is contraindicated in pregnancy. First trimester: high risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and postmarketing data. Second/third trimester: associated with fetal growth restriction, oligohydramnios, and fetal death. Use only if no alternative and patient is fully informed; consider emergency contraception if exposure occurs. |
| Fetal Monitoring | Monitor maternal renal function, liver enzymes, and blood counts monthly during treatment. Perform fetal ultrasound for growth and amniotic fluid volume every 4 weeks if exposed in second/third trimester. Consider fetal echocardiography if exposure in first trimester. |
| Fertility Effects | Reversible impairment of spermatogenesis and oogenesis observed in animal studies. Reduced fertility reported in humans; advise pre-treatment fertility counseling. Effects likely resolve after drug discontinuation. |
| Clinical Pearls | Lotusate is a barbiturate (secobarbital) used for short-term treatment of insomnia. Due to high abuse potential and rapid tolerance, limit use to 7-10 days. Avoid in patients with porphyria, severe hepatic impairment, or respiratory depression. Monitor for paradoxical excitation in elderly. Do not administer intravenously as it may cause severe hypotension or apnea. Half-life is 15-40 hours; accumulation occurs with repeated dosing. Abrupt discontinuation after prolonged use may precipitate withdrawal seizures. |
| Patient Advice | Take exactly as prescribed; do not increase dose or duration without consulting your doctor. · Do not consume alcohol or other CNS depressants (e.g., benzodiazepines, opioids) while taking this medication. · This medication may cause drowsiness, dizziness, or impaired coordination – avoid driving or operating machinery until you know how it affects you. · Do not stop taking suddenly after long-term use; your doctor will taper the dose to prevent withdrawal symptoms. · Store in a safe place out of reach of others; misuse can cause addiction, overdose, or death. · If you miss a dose, skip it and take the next dose at the regular time – do not double the dose. · Report any signs of allergic reaction (rash, swelling, difficulty breathing) or unusual changes in mood or behavior immediately. |